These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30231203)

  • 21. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
    Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
    Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.
    Quaranta V; Rainer C; Nielsen SR; Raymant ML; Ahmed MS; Engle DD; Taylor A; Murray T; Campbell F; Palmer DH; Tuveson DA; Mielgo A; Schmid MC
    Cancer Res; 2018 Aug; 78(15):4253-4269. PubMed ID: 29789416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
    Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
    Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
    Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
    Chen X; Zhou W; Liang C; Shi S; Yu X; Chen Q; Sun T; Lu Y; Zhang Y; Guo Q; Li C; Zhang Y; Jiang C
    Nano Lett; 2019 Jun; 19(6):3527-3534. PubMed ID: 31058513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
    Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
    Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
    You J; Zhao J; Wen X; Wu C; Huang Q; Guan F; Wu R; Liang D; Li C
    J Control Release; 2015 Mar; 202():40-8. PubMed ID: 25637565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.